Proteon Therapeutics Inc (NASDAQ:PRTO) has been assigned an average recommendation of “Hold” from the nine analysts that are presently covering the company. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $3.40.
A number of analysts have issued reports on the company. Robert W. Baird reissued a “neutral” rating and issued a $3.00 target price on shares of Proteon Therapeutics in a research report on Thursday, March 16th. HC Wainwright lowered Proteon Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $18.00 to $3.00 in a report on Friday, March 17th. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price target on shares of Proteon Therapeutics in a report on Thursday, March 16th. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Proteon Therapeutics in a report on Tuesday, January 17th. Finally, Zacks Investment Research raised Proteon Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Tuesday, March 21st.
Proteon Therapeutics (NASDAQ:PRTO) traded down 7.14% during midday trading on Monday, hitting $1.30. The stock had a trading volume of 74,705 shares. Proteon Therapeutics has a 52 week low of $1.30 and a 52 week high of $11.45. The stock’s market capitalization is $21.58 million. The company’s 50 day moving average price is $1.57 and its 200-day moving average price is $4.01.
Several institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new position in Proteon Therapeutics during the fourth quarter worth approximately $635,000. Pharmstandard International S.A. bought a new position in Proteon Therapeutics during the fourth quarter worth approximately $2,214,000. Baker BROS. Advisors LP bought a new position in Proteon Therapeutics during the third quarter worth approximately $2,786,000. Finally, Spark Investment Management LLC bought a new position in Proteon Therapeutics during the third quarter worth approximately $107,000. 49.28% of the stock is owned by hedge funds and other institutional investors.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.